Cognito Therapeutics
Cognito Therapeutics, Inc. is seeking a Principal Software Developer to lead the design, development, and maintenance of high-quality software solutions that support their neurodegenerative disease therapies. The role involves collaboration with cross-functional teams, leadership, mentorship, and overseeing the full software development lifecycle.
Headquarters
Cambridge, Massachusetts, United States
Company Size
11-50 employees
Founded
2016
Cognito Therapeutics is a clinical-stage neurotechnology company developing non-invasive, neuroprotective therapies for Alzheimer's disease and other neurodegenerative conditions. Its lead platform, Spectris, uses audiovisual stimulation to evoke gamma wave brain activity with the goal of preserving cognition, brain volume, and daily function in Alzheimer's patients. Spectris AD has received FDA Breakthrough Device Designation and is designed to be administered by patients at home for one hour per day.
Cognito Therapeutics Announces Oversubscribed $105 Million Series C Financing to Advance Spectris™ in Alzheimer’s Disease
1 week ago
Top digital health funding: Grow Therapy reaches $3B valuation
3 days ago
Cognito Therapeutics raises $105M for neurotechnology platform for Alzheimer's
1 week ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Cognito Therapeutics.
13% above the average for this role
Cognito Therapeutics Raises $105M Series C Led by Morningside Ventures to Advance Spectris Platform for Alzheimer’s
1 week ago